Click for best price
Commercializing BiomarkersTherapeutic Diagnostic Market Size, Share 2023
| Market size in 2022 |
US$ 22010 million
|
Forecast Market size by 2029 |
US$ 30140 million
|
| Growth Rate |
CAGR of 4.6% |
Number of Pages |
107 Pages |
A biomarker is, according to the US National Institutes of Health, ?a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.?
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
? Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
? Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
? Proteomic biomarkers: Base on the analysis of the protein profiles.
? Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications. This report contains market size and forecasts of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in global, including the following market information:
- Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at US$ 22010 million in 2022 and is projected to reach US$ 30140 million by 2029, at a CAGR of 4.6% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
We surveyed the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Type, 2022 (%)
- Consumables
- Services
- Software
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Application, 2022 (%)
- Oncology
- Cardiology
- Neurology
- Other
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues share in global market, 2022 (%)
- Further, the report presents profiles of competitors in the market, key players include:
- Roche
- Dako (Agilent Technologies)
- Merck
- BD
- Abbott
- Genesys Biolabs (20/20GeneSystems)
- Affymetrix
- Agendia
- ALMAC
- Arrayit
- Biocartic
- BG Medicine
- KEGG EXPRESSION Database
- Thermo Fisher
- BGI
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Commercializing Biomarkers in Therapeutic and Diagnostic Applications, market overview.
- Chapter 2: Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size in revenue.
- Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 22010 million
|
| Forecast Market size by 2029 |
US$ 30140 million
|
| Growth Rate |
CAGR of 4.6% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
107 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Overall Market Size
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size: 2022 VS 2029
2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in Global Market
3.2 Top Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Ranked by Revenue
3.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Companies
3.4 Top 3 and Top 5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies in Global Market, by Revenue in 2022
3.5 Global Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type
3.6 Tier 1, Tier 2 and Tier 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in Global Market
3.6.1 List of Global Tier 1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies
3.6.2 List of Global Tier 2 and Tier 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Markets, 2022 & 2029
4.1.2 Consumables
4.1.3 Services
4.1.4 Software
4.2 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue & Forecasts
4.2.1 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2023
4.2.2 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2024-2029
4.2.3 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2022 & 2029
5.1.2 Oncology
5.1.3 Cardiology
5.1.4 Neurology
5.1.5 Other
5.2 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue & Forecasts
5.2.1 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2023
5.2.2 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2024-2029
5.2.3 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2022 & 2029
6.2 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue & Forecasts
6.2.1 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2023
6.2.2 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2024-2029
6.2.3 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2029
6.3.2 US Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.3.3 Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.3.4 Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2029
6.4.2 Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4.3 France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4.4 U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4.5 Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4.6 Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4.7 Nordic Countries Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.4.8 Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2029
6.5.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.5.3 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.5.4 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.5.5 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.5.6 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2029
6.6.2 Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.6.3 Argentina Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2029
6.7.2 Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.7.3 Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.7.4 Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
6.7.5 UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2018-2029
7 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Dako (Agilent Technologies)
7.2.1 Dako (Agilent Technologies) Company Summary
7.2.2 Dako (Agilent Technologies) Business Overview
7.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.2.5 Dako (Agilent Technologies) Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 BD
7.4.1 BD Company Summary
7.4.2 BD Business Overview
7.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.4.5 BD Key News & Latest Developments
7.5 Abbott
7.5.1 Abbott Company Summary
7.5.2 Abbott Business Overview
7.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.5.5 Abbott Key News & Latest Developments
7.6 Genesys Biolabs (20/20GeneSystems)
7.6.1 Genesys Biolabs (20/20GeneSystems) Company Summary
7.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
7.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.6.5 Genesys Biolabs (20/20GeneSystems) Key News & Latest Developments
7.7 Affymetrix
7.7.1 Affymetrix Company Summary
7.7.2 Affymetrix Business Overview
7.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.7.5 Affymetrix Key News & Latest Developments
7.8 Agendia
7.8.1 Agendia Company Summary
7.8.2 Agendia Business Overview
7.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.8.5 Agendia Key News & Latest Developments
7.9 ALMAC
7.9.1 ALMAC Company Summary
7.9.2 ALMAC Business Overview
7.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.9.5 ALMAC Key News & Latest Developments
7.10 Arrayit
7.10.1 Arrayit Company Summary
7.10.2 Arrayit Business Overview
7.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.10.5 Arrayit Key News & Latest Developments
7.11 Biocartic
7.11.1 Biocartic Company Summary
7.11.2 Biocartic Business Overview
7.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.11.5 Biocartic Key News & Latest Developments
7.12 BG Medicine
7.12.1 BG Medicine Company Summary
7.12.2 BG Medicine Business Overview
7.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.12.5 BG Medicine Key News & Latest Developments
7.13 KEGG EXPRESSION Database
7.13.1 KEGG EXPRESSION Database Company Summary
7.13.2 KEGG EXPRESSION Database Business Overview
7.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.13.5 KEGG EXPRESSION Database Key News & Latest Developments
7.14 Thermo Fisher
7.14.1 Thermo Fisher Company Summary
7.14.2 Thermo Fisher Business Overview
7.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.14.5 Thermo Fisher Key News & Latest Developments
7.15 BGI
7.15.1 BGI Company Summary
7.15.2 BGI Business Overview
7.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2018-2023)
7.15.5 BGI Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Opportunities & Trends in Global Market
Table 2. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers in Global Market
Table 3. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints in Global Market
Table 4. Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Global Market
Table 5. Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Companies, 2018-2023
Table 8. Global Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type
Table 9. List of Global Tier 1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2024-2029
Table 30. Roche Company Summary
Table 31. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 32. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Dako (Agilent Technologies) Company Summary
Table 35. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 36. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 37. Dako (Agilent Technologies) Key News & Latest Developments
Table 38. Merck Company Summary
Table 39. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 40. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 41. Merck Key News & Latest Developments
Table 42. BD Company Summary
Table 43. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 44. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 45. BD Key News & Latest Developments
Table 46. Abbott Company Summary
Table 47. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 48. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 49. Abbott Key News & Latest Developments
Table 50. Genesys Biolabs (20/20GeneSystems) Company Summary
Table 51. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 52. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 53. Genesys Biolabs (20/20GeneSystems) Key News & Latest Developments
Table 54. Affymetrix Company Summary
Table 55. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 56. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 57. Affymetrix Key News & Latest Developments
Table 58. Agendia Company Summary
Table 59. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 60. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 61. Agendia Key News & Latest Developments
Table 62. ALMAC Company Summary
Table 63. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 64. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 65. ALMAC Key News & Latest Developments
Table 66. Arrayit Company Summary
Table 67. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 68. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 69. Arrayit Key News & Latest Developments
Table 70. Biocartic Company Summary
Table 71. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 72. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 73. Biocartic Key News & Latest Developments
Table 74. BG Medicine Company Summary
Table 75. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 76. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 77. BG Medicine Key News & Latest Developments
Table 78. KEGG EXPRESSION Database Company Summary
Table 79. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 80. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 81. KEGG EXPRESSION Database Key News & Latest Developments
Table 82. Thermo Fisher Company Summary
Table 83. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 84. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 85. Thermo Fisher Key News & Latest Developments
Table 86. BGI Company Summary
Table 87. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 88. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn) & (2018-2023)
Table 89. BGI Key News & Latest Developments
List of Figures
Figure 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Type in 2022
Figure 2. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Application in 2022
Figure 3. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2022
Figure 8. By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 9. By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 10. By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 12. By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 14. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 15. By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 16. US Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 20. Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 21. France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 28. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 32. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 34. Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2018-2029
Figure 37. Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2018-2029
Figure 41. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
